Navigation Links
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Date:12/18/2007

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers. Developed as a tumor-targeted anticancer agent, that actively seeks out and destroys metastatic cancers, Rexin-G exhibits unprecedented single-agent efficacy where other agents, including targeted biologics, have failed. Moreover, Rexin-G has established an exemplary record of clinical safety, virtually eliminating the systemic toxicities routinely encountered with chemotherapies, thus enhancing quality of life.

*(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

This recent regulatory approval and licensure of Rexin-G in the Philippines is noteworthy in that Rexin-G(R) is among the first gene-based medicines to be approved anywhere in the world, and remarkable in that it is the first targeted gene delivery system ever developed that actually works in humans. However, such individual accomplishments are rarely heralded by the intrepid physicians and scientists at Epeius Biotechnologies, whose mission runs contrary to so many blue-sky biotechnology companies that are quick to "sell (i.e., promote) the story," only to disappoint the patients, who remain the most vulnerable of society.

According to Dr. Frederick L. Hall, President and CEO of Epeius, "It is most fitting that Rexin-G receives its first product registration in the Philippines which brought forth the stellar physician-scientist whose drive and determination to engineer a better medicine made Rexin-G possible, and also it was first in the Philippines where the dedicated clinicians, oncologists, regulatory authorities, and medical institutions worked tirelessly for years to bring this targeted genetic medicine to the
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...ore, make a donation or send a Christmas Seals e-c...ewswire/ -- Millions will receive Christmas Seals ...ung Association. These decorative holiday stamps a...back to 1907 when the Lung Association led efforts...cans alive today have no vivid memories of how wid...
(Date:11/18/2008)... Influenza survey underscores that mothers need to...and Gold Medalist Kristi Yamaguchi joins initiativ...While 78 percent of mothers in the United States c...reatening disease that can strike anyone, only hal...ted this season, according to a new survey from th...
(Date:11/13/2008)...ments Prior to Surgery, ARLINGTON HEIGHTS, Ill., ...nutrition before surgery in massive weight loss pa...decrease surgical complications, accelerate,wound ...ergy levels,according to a study in the December ...e official medical journal of the American Society...
(Date:11/12/2008)...son, Marilyn & James Simons and,Sherry Lansing at ... J. Craig Venter,Ph.D....titute (JCVI), was,awarded the Double Helix Medal ...ber 6th at a gala event in New York City., Dr. Ve.... James D.,Watson for making each of their individ...
Breaking Medicine Technology:American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2Nutrition 21 Introduces New Product 3A Iceland Health Skin Rejuvenation 28TM 29 22033 1Nutrition 21 Introduces New Product 3A Iceland Health Skin Rejuvenation 28TM 29 22033 2Nutrition 21 Introduces New Product 3A Iceland Health Skin Rejuvenation 28TM 29 22033 3Ease of Use and Intuitive Nature of the DATATRAK eClinical 28TM 29 Platform Allows for Further Operational Efficiencies 22030 1Ease of Use and Intuitive Nature of the DATATRAK eClinical 28TM 29 Platform Allows for Further Operational Efficiencies 22030 2Ease of Use and Intuitive Nature of the DATATRAK eClinical 28TM 29 Platform Allows for Further Operational Efficiencies 22030 3Ease of Use and Intuitive Nature of the DATATRAK eClinical 28TM 29 Platform Allows for Further Operational Efficiencies 22030 4Chicos Hosts Jacket Design Contest to Benefit Charity 22027 1Chicos Hosts Jacket Design Contest to Benefit Charity 22027 2Pharsight to Present on Literature Based Disease Modeling Approaches at AAPS National Biotechnology Conference 6035 1Pharsight to Present on Literature Based Disease Modeling Approaches at AAPS National Biotechnology Conference 6035 2
...lynx today announced positive,interim results from... programme, ALX-0081, an anti-thrombotic treatment... therapeutic,Nanobody® targeting von Willebran...bosis in patients with acute coronary,syndrome. , ...d to assess,safety, tolerability and pharmacokinet...
...n with at least three sites of,cellular atypia in ...han average women to develop breast cancer, accord... study of women with atypical,hyperplasia. The fin...rnal of Clinical Oncology., Several previous studi...ed atypia) in breast tissue is a major risk factor...
Other Medicine Technology:Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 2Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 3
(Date:11/21/2008)... do not cause genetic damage that can lead to dise... -- Two popular medications for treating attention...e genetic damage linked to an increased risk for d..., done by researchers at Duke University Medical C...ers a previous one that reported biomarkers associ...
(Date:11/21/2008).../ -- In a statewide survey, 33 physicians credenti...y at Presbyterian Hospital of Dallas were honored ... Super Doctors ." , , Each year, the publis... Media, Inc. to survey more than 38,000 medical pr...you needed medical care, which doctor would you ch...
(Date:11/21/2008)...wswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: ...s to the global orthopedic device industry and oth...Moore, President and Chief Executive Officer, and ...ncial Officer, are scheduled to present at the 20t...he New York Palace Hotel on Wednesday, December 3,...
(Date:11/21/2008)...he University of Texas M. D. Anderson Cancer Cente...o eradicate breast cancer in Panama through the Pa... of the Americas today at an event with Laura Bush...Fernndez de Torrijos, the First Lady of Panama. ...he U.S. Department of State and Susan G. Komen for...
Breaking Medicine News(10 mins):Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2
...e cancer puts men at increased risk for diabetes a...servational study published in the// Sept. 20 Jour...er have high five-year survival rates, but they al...rtality than healthy men,” says study author Nancy...
...and Chile announced a tax on airline tickets to ra...ients who cannot afford them//. Representatives fr...Chirac of France and Luis Ignacio Lula da Silva of...ment at the UN. UN Secretary General Kofi Annan an...
...s revealed that Maori are almost twice as likely t...y to suffer// from mental disorder generally than ...Health Ministry has been the first to shed light o... disorders among different ethnic groups in this c...
...t increased levels of lipoprotein(a)are linked wit...healthy women according to Boston-based investigat...ralized screening of lipoprotein(a) in the populat...igh levels were associated with cardiovascular ris...
Other Medicine News:Health News:Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease 2Health News:High lipoprotein Levels in women Linked to Cardiovascular Risk 2
...dus laser lens design with Volk exclusive Double A...ion viewing and treatment of the optic nerve head ...heric optics provide improved performance over exi...mes standard with LaserWindow® for optimal las...
...Laser Lens affords the practitioner a direct uprig...izing a unique solid methyl methacrylate optic wit...erior, this special optical design eliminates fila...us lenses. Available in Volk's exclusive ANF+ (Adv...
...® is excellent for critically evaluating and t...from macular degeneration, retinal vascular occlus...ic retinopathy and other retinal conditions. It is...ns providing excellent magnification combined with...
...s designed for focal laser therapy and mid-to-far ...sign presents a realistic contour of the retinal c...f the entire posterior pole extending to the equat...c movement on the globe, therefore increasing its ...
Medicine Products: